MTD:NYSEMettler-Toledo International, Inc. Analysis
Data as of 2026-06-18 - not real-time
$1,144.84
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Mettler‑Toledo (MTD) is trading at $1,144.84, just above its 20‑day SMA of $1,143.92 but well below the 50‑day ($1,195.84) and 200‑day ($1,315.30) averages, indicating a bearish price trend. The RSI sits near the neutral 48 level and the MACD shows a bullish signal despite a negative line, while volume is decreasing and 30‑day volatility is high at 58.5%, suggesting short‑term price pressure. Fundamentally, the company delivered a 7.2% revenue growth, strong gross margin of 59% and operating margin of 23%, and beat Q1 earnings, prompting analysts to upgrade to a “buy” consensus. However, the DCF‑derived fair value of $437.16 is far below the current price, yielding an upside/downside metric of –15.9% and flagging the stock as significantly overvalued. Analyst coverage is positive, with a median target of $1,320, implying roughly 15% upside from current levels.
The lack of dividend payments and a negative book‑value per share (-$2.07) further limit income‑focused investors, while the company’s global exposure—especially noted geopolitical uncertainty in Europe—adds medium‑level geographic and regulatory risk. Overall, the stock’s strong cash generation and margin profile support a medium‑term buy case, but the current valuation gap and technical weakness counsel caution in the short term.
The lack of dividend payments and a negative book‑value per share (-$2.07) further limit income‑focused investors, while the company’s global exposure—especially noted geopolitical uncertainty in Europe—adds medium‑level geographic and regulatory risk. Overall, the stock’s strong cash generation and margin profile support a medium‑term buy case, but the current valuation gap and technical weakness counsel caution in the short term.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price below 50‑day and 200‑day moving averages
- Decreasing volume and high short‑term volatility
- Current price far exceeds DCF fair value
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Q1 earnings beat and raised EPS guidance
- Strong revenue growth and high operating margins
- Analyst consensus “buy” with median target ~15% above price
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Sustained cash generation but negative book value
- Overvaluation relative to intrinsic fair value
- Exposure to global macro‑economic and regulatory environments
Key Metrics & Analysis
Financial Health
Revenue Growth7.20%
Profit Margin21.40%
P/E Ratio26.9
ROA20.57%
P/B Ratio-552.3
Op. Cash Flow$901.1M
Free Cash Flow$615.0M
Industry P/E24.1
Technical Analysis
TrendBearish
RSI48.3
Support$1,056.83
Resistance$1,198.02
MA 20$1,143.92
MA 50$1,195.84
MA 200$1,315.30
MACDBullish
VolumeDecreasing
Fear & Greed Index92.14
Valuation
Fair Value$437.16
Target Price$1,327.83
Upside/Downside15.98%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.99
Volatility58.53%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.